Skip to main content

Table 2 Demographics and baseline characteristics

From: New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence

Author
(year)
N D (W) Agea (years) Femaleb (%) Weighta (Kg) Patients on statinb (%) TGa (mg/dL) LDL-Ca (mg/dL) HDL-Ca (mg/dL) TCa
(mg/dL)
Non-HDL-Ca
(mg/dL)
HbA1ca (%) ALTa (IU/L)
Shetty et al. (2015) [13] 2804 12 53.0 ± 10.0 37.5 72.3 ± 11.5 57.8 312.3 ± 122.7 139.5 ± 42.2 38.8 ± 8.7 240.2 ± 63.0 201.8 ± 64.1 8.3 ± 1.3  
Thacker et al. (2016) [14] 50 12 49.6 42.0   100.0 272.0 88.8 39.3 159.9   7.5 68.8
Joshi et al. (2018) [15] 18 12      1265.9 ± 394.3     320.8 ± 172.8 8.9 ± 1.7  
Bhattacharyya et al. (2018) [16] 60 12    79.1 ± 9.6   219.9 ± 178.8 108.3 ± 46.9 38.9 ± 9.8 175.9 ± 56.9 157.3 ± 53.4 7.9 ± 1.5  
Saboo et al. (2015) [17] 31 24      259.3 ± 37.9      9.0 ± 1.3 64.1 ± 6.2
Joshi et al. (2016) [18] 221 24 58.0 41.6   48.0 321.0      8.9 89.0
Chhaya et al. (2017) [19] 78 24    78.6 ± 9.8 85.0 348.7 ± 162.7 103.4 ± 26.0   192.8 ± 61.9   8.7 ± 1.4  
Mohit et al. (2017) [20] 50 24 58.6 ± 14.0 42.0 74.2 ± 13.6 100.0 212.9 ± 47.6 157.1 ± 75.6 48.9 ± 12.7 224.6 ± 28.1   8.8 ± 0.5  
Kaul et al. (2019) [21] 104 24 59.1 ± 11.4 22.1 73.2 ± 11.2 100.0 357.0 ± 332.0 91.0 ± 37.0 37.5 ± 16.6 176.0 ± 62.0 140.0 ± 55.0 7.9 ± 1.6  
Goyal et al. (2019) [22] 84 24 51.4 ± 10.3 26.2    334.7 ± 74.0      7.9 ± 0.5 98.0 ± 32.0
Chatterjee et al. (2015) [23] 31 27 54.0 ± 9.9 42.0 69.4 ± 9.9 68.0 335.5 ± 161.2 111.4 ± 46.9 39.2 ± 10.7 197.5 ± 52.6 161.4 ± 52.8 8.1 ± 1.8 52.1 ± 26.7
Joshi et al. (2015) [24] 787 36 53.0 35.6 73.9 ± 11.9 50.2 297.9 ± 122.6 132.5 ± 47.9 41.0 ± 14.7 239.9 ± 74.7 199.0 ± 76.5 8.5 ± 1.4  
Chatterjee et al. (2016) [25] 74 40 52.4 ± 9.6 37.8 68.0 ± 10.5 65.0 343.3 ± 211.7 105.2 ± 41.9 38.3 ± 10.6 186.3 ± 50.8 150.2 ± 50.4 7.8 ± 1.7 43.2 ± 24.2
Joshi et al. (2015) [26] 236 52 52.0 ± 10.0    38.6 316.0 ± 139.0 131.8 ± 43.8 42.5 ± 8.7   194.0 ± 48.5 8.5 ± 1.1  
Aneja et al. (2016) [27] 81 52 55.4 28.4   81.5 294.1 ± 83.9   41.4 ± 4.6 224.9 ± 29.9 183.1 ± 33.8 8.1 ± 0.7  
Maheshwari et al. (2016) [28] 106 52 54.8 34.0   99.0 252.7 ± 58.3 165.7 ± 49.7   223.8 ± 33.9 164.4 ± 33.9 8.2  
Chatterjee et al. (2017) [29] 851 52 53.0   66.8   295.1 ± 101.9 140.1 ± 31.4   234.6 ± 41.9 199.3 ± 42.5 11.3 ± 2.2  
Chatterjee et al. (2018) [30] 158 58 51.3 ± 10.9 32.3 70.5 ± 2.1 74.7 315.4 ± 176.3 101.8 ± 41.9 38.4 ± 10.2 180.7 ± 50.9 139.5 ± 56.3 7.9 ± 1.6 42.2 ± 26.6
  1. Blank cells indicate data not available in the respective studies
  2. N: Total number of patients on Saroglitazar 4 mg; D: study duration; W: weeks; M: mean; SD: standard deviation; TG: triglyceride; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; non-HDL-C: non high-density lipoprotein cholesterol; HbA1c: glycosylated hemoglobin; ALT: alanine aminotransferase
  3. aData for age, weight, TG, LDL-C, HDL-C, TC, non-HDL-C, HbA1c and ALT are presented in M or M ± SD
  4. bData for female and patients on statin are presented in percentage (%)